Clinical Trials

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT07332351 2026-03-13

TRIFECTA

33 enrolled

Urinary Bladder Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

34 enrolled

Urinary Bladder Neoplasms

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

25 enrolled

Urinary Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06972615 2026-02-17

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

37 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

46 enrolled

Urinary Bladder Neoplasms

NCT03587662 2026-01-09

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

30 enrolled

Carcinoma, Renal Cell

NCT04553939 2026-01-02

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

50 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07296705 2025-12-22

HARBOR

25 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT05975307 2025-12-01

BCIRT-01

71 enrolled

Urinary Bladder Neoplasms

NCT04386746 2025-11-17

GEMDOCE

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02621151 2025-10-07

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

60 enrolled 11 charts

Muscle-invasive Urothelial Cancer of the Bladder

NCT07189793 2025-09-24

OHAI-NMIBC-01

106 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07184021 2025-09-19

No Acronym

30 enrolled

Urinary Bladder Neoplasms

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

46 enrolled

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06571708 2025-09-02

NeoSTOP-IT

36 enrolled

Urinary Bladder Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

150 enrolled

Carcinoma, Transitional Cell, Neoplasms

NCT01261728 2025-08-08

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

57 enrolled

Carcinoma, Transitional Cell

NCT07043972 2025-07-20

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

55 enrolled

Carcinoma, Transitional Cell

NCT06663137 2025-06-13

HGNMIBC

70 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07019220 2025-06-13

COBRA

47 enrolled

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT04602078 2025-04-24

AUREA

82 enrolled 20 charts

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT06257017 2025-04-04

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

20 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT05024734 2025-03-11

GAIN INST

34 enrolled

Urinary Bladder Neoplasms

NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

87 enrolled 13 charts

Metastatic Bladder Urothelial Carcinoma

NCT00627432 2025-02-18

Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

44 enrolled

Urinary Bladder Neoplasms

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

120 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Phase 2 Terminated

6 enrolled 12 charts

Urinary Bladder Neoplasms

NCT04861584 2024-12-04

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

41 enrolled

Urinary Bladder Neoplasms

NCT06623162 2024-10-04

SASAN-SPARING

70 enrolled

Mibc

NCT02177695 2024-09-19

COXEN

237 enrolled 20 charts

Urinary Bladder Neoplasms

NCT00936936 2024-08-26

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

64 enrolled 10 charts

Testicular Neoplasms

NCT05531123 2024-07-12

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

30 enrolled